Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Mol Med ; 21(3): 211-220, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33109060

RESUMO

Cancer is one of the most important disorders which is associated with high mortality and high costs of treatment for patients. Despite several efforts, finding, designing and developing, new therapeutic platforms in the treatment of cancer patients are still required. Utilization of microorganisms, particularly bacteria has emerged as new therapeutic approaches in the treatment of various cancers. Increasing data indicated that bacteria could be used in the production of a wide range of anti-cancer agents, including bacteriocins, antibiotics, peptides, enzymes, and toxins. Among these anti-cancer agents, bacteriocins have attractive properties, which make them powerful anti-cancer drugs. Multiple lines evidence indicated that several bacteriocins (i.e., colcins, nisins, pediocins, pyocins, and bovocins) via activation/inhibition different cellular and molecular signaling pathways are able to suppress tumor growth in various stages. Hence, identification and using various bacteriocins could lead to improve and introduce them to clinical practices. Here, we summarized various bacteriocins which could be employed as anti-cancer agents in the treatment of many cancers.


Assuntos
Antineoplásicos/uso terapêutico , Bacteriocinas/uso terapêutico , Neoplasias/tratamento farmacológico , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Neoplasias/genética , Neoplasias/patologia , Nisina/uso terapêutico , Pediocinas/uso terapêutico , Piocinas/uso terapêutico , Transdução de Sinais/efeitos dos fármacos
2.
Antimicrob Agents Chemother ; 55(12): 5469-74, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21947394

RESUMO

AvR2-V10.3 is an engineered R-type pyocin that specifically kills Escherichia coli O157, an enteric pathogen that is a major cause of food-borne diarrheal disease. New therapeutics to counteract E. coli O157 are needed, as currently available antibiotics can exacerbate the consequences of infection. We show here that orogastric administration of AvR2-V10.3 can prevent or ameliorate E. coli O157:H7-induced diarrhea and intestinal inflammation in an infant rabbit model of infection when the compound is administered either in a postexposure prophylactic regimen or after the onset of symptoms. Notably, administration of AvR2-V10.3 also reduces bacterial carriage and fecal shedding of this pathogen. Our findings support the further development of pathogen-specific R-type pyocins as a way to treat enteric infections.


Assuntos
Antibacterianos/uso terapêutico , Diarreia/tratamento farmacológico , Diarreia/prevenção & controle , Escherichia coli O157/efeitos dos fármacos , Piocinas/uso terapêutico , Animais , Animais Recém-Nascidos , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Carga Bacteriana/efeitos dos fármacos , Diarreia/microbiologia , Diarreia/fisiopatologia , Modelos Animais de Doenças , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/prevenção & controle , Escherichia coli O157/patogenicidade , Fezes/microbiologia , Engenharia Genética/métodos , Humanos , Piocinas/administração & dosagem , Piocinas/farmacologia , Coelhos , Resultado do Tratamento
4.
J Med Microbiol ; 9(2): 153-61, 1976 May.
Artigo em Inglês | MEDLINE | ID: mdl-819653

RESUMO

The interactions of a contractile, a filamentous and a small pyocine with a sensitive strain of Pseudomonas aeruginosa (no. P14) were examined in vivo. The purification procedure used yielded high-activity pyocine preparations that were not toxic to mice. The inhibitory activity of such preparations, when injected into mice by various routes, was retained for up to 24 h. However, high molecular-weight pyocines given intraperitoneally in the presence of a lethal dose of strain P14 administered by the same route did not prevent the fatal outcome of infection unless they are given before or together with the bacteria. The small pyocine had no protective effect. In burned mice infected with strain P14, topical application of a filamentous pyocine failed to improve the chances of survival. The results suggest that there is little future for pyocine therapy.


Assuntos
Bacteriocinas/uso terapêutico , Infecções por Pseudomonas/tratamento farmacológico , Pseudomonas aeruginosa/efeitos dos fármacos , Piocinas/uso terapêutico , Administração Tópica , Animais , Queimaduras/complicações , Queimaduras/tratamento farmacológico , Feminino , Injeções Intraperitoneais , Injeções Intravenosas , Injeções Subcutâneas , Camundongos , Infecções por Pseudomonas/complicações , Pseudomonas aeruginosa/metabolismo , Piocinas/biossíntese , Piocinas/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...